Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
A major hurdle in Alzheimer disease research is the failure of mouse models to capture complexities of the human brain that contributes to repeated clinical trial failure.
Why it matters
This paper discusses the challenges of using brain organoid models for Alzheimer's disease and related tauopathies and proposes a benchmarking framework for making them more translationally useful. It is a methods and modeling discussion and does not report any treatment, cure, or prevention for patients.
-
Accurate estimation of Alzheimer's disease (AD) severity from structural magnetic resonance imaging (MRI) remains difficult, as disease-associated anatomical alterations are often subtle and publicly available datasets are typically too small to support robust deep learning model training.
Why it matters
In 214 OASIS-1 subjects, a lightweight 2D CNN trained from scratch recovered only a broad normal-versus-impaired signal (AUC 0.59) and was at chance on adjacent-stage tasks. The authors describe this as a methodological proof of concept, not a clinically deployable diagnostic tool, and it does not address treatment or cure.
-
Among 871 participants (mean age: 62.80 ± 6.02 years), every SD increase in AIx and RI scores was both associated with 0.010 pg/mL (95% CI: 0.003–0.017, p = 0.004) higher blood p-tau217 levels after adjustment for age, employment status, BMI, mild cognitive impairment, hypertension, cholesterol-HDL ratio, renal function, and ApoE4 carrier status.
Why it matters
In midlife women without dementia, higher arterial stiffness and pressure wave reflection measures were associated with higher blood p-tau217 levels. These measures may serve as markers of risk for tau-related brain pathology, though the study was cross-sectional and cannot show cause and effect.
-
Cognitively impaired patients with negative biomarkers of amyloidosis but with neurochemical evidence of Tau pathophysiology or neurodegeneration or both are classified as "suspected non-Alzheimer pathophysiology" (SNAP), according to the 2018 research framework for a biological definition of Alzheimer's disease (AD).
Why it matters
This retrospective study looked at survival outcomes in patients classified as having suspected non-Alzheimer pathophysiology, based on negative amyloid biomarkers with evidence of tau pathophysiology or neurodegeneration. It is about characterizing this group and its outcomes, not about any treatment, cure or prevention.
-
42/100
This cross-sectional study examines the quality of information on Alzheimer disease (AD) monoclonal antibodies presented by news websites.
Why it matters
This cross-sectional study examines the quality of information about Alzheimer disease monoclonal antibodies presented by news websites. It does not test any treatment, so it shows nothing about treating, curing or preventing the disease.
-
AD risk was associated with shorter TL (β = -0.48, P < 2 × 10–16).
Why it matters
Shorter telomere length was associated with Alzheimer's disease risk, and genome-wide significant interactions between telomere length and genetic variants were identified across multiple ancestral populations. These findings suggest that telomere maintenance pathways may be central to Alzheimer's pathogenesis.
-
Internal consistency of the ACE-III was strong (McDonald's ω = 0.889).
Why it matters
The Polish version of the ACE-III showed strong internal consistency and better diagnostic accuracy than the MMSE for distinguishing controls from mild cognitive impairment and mild cognitive impairment from Alzheimer's disease dementia. This supports its use in timely diagnosis, but it is a cognitive screening tool and does not treat or prevent dementia.
-
42/100
Individuals with Alzheimer’s dementia exhibited poorer nutritional status (EdFED: 8.0 vs. 2.0; NUFFE: 10.0 vs. 7.0; both p < 0.001) and lower adherence to the Mediterranean diet (6.0 vs. 7.0; p = 0.050).
Why it matters
This study found that people with Alzheimer's dementia had poorer nutritional status and lower Mediterranean diet adherence than those without. It shows associations only, so it cannot prove that diet or feeding changes prevent or treat dementia.
-
Emerging evidence suggests that viral infections may contribute to the onset and progression of Alzheimer's disease (AD) and other forms of dementia.
Why it matters
This review describes evidence that viral infections linked to Alzheimer's disease and related dementias can cause cells to produce reactive oxygen species, which may contribute to these conditions. It is a review of experimental evidence and does not test any treatment, cure or prevention.
-
Female Psen1 mutation(L166P) mice were found to have reductions in whole-body mineral density (BMD) and bone mineral content as early as one month and a sustained bone phenotype with age with loss in cortical and trabecular properties compared to age-and gendermatched wildtype control mice, whereas male mice did not (Fig.1A-C).
Why it matters
In several mouse models of Alzheimer's disease, imaging showed sex-specific changes in bone architecture, with female Psen1 mutant mice showing reduced bone mineral density early and sustained bone loss. This is a preclinical animal study and does not test any treatment, cure or prevention for Alzheimer's disease in people.
-
A total of 7031 AD patients were identified.
Why it matters
Among 7031 Alzheimer's disease patients, those with neuropsychiatric symptoms were prescribed different psychotropic medications depending on whether they were non-Hispanic White or non-Hispanic Black. This describes disparities in prescribing patterns, not the effectiveness of any treatment for the disease.
-
This review article discusses the FDA's May 2025 clearance of Fujirebio's Lumipulse G blood test, the first FDA-cleared blood test for aiding Alzheimer's diagnosis (via the pTau217/beta-amyloid 1-42 ratio).
Why it matters
The FDA cleared the Lumipulse G blood test in May 2025 to help diagnose Alzheimer's in symptomatic adults 55 and older in specialized care, correctly ruling in amyloid pathology in over 90% of positive cases and ruling it out in about 97% of negative cases. It is not approved for screening people without symptoms or for distinguishing Alzheimer's from other brain diseases, and it has not been well validated across diverse racial and ethnic groups.
-
The efficacy of acetylcholinesterase inhibitors (AChEI) and memantine (ME) in severe dementia remains uncertain, and real world data are limited.
Why it matters
In this group of patients with severe dementia, those taking both an acetylcholinesterase inhibitor and memantine had slower cognitive decline and lower mortality than those taking neither. Memantine alone was also linked to lower mortality, but this was an observational study, so it cannot prove that these drugs caused the differences.
-
Alzheimer's disease (AD), first identified by Dr. Alois Alzheimer in 1906, has evolved from a rare presenile dementia to a global health crisis affecting over 58 million people as of 2020, with projections reaching 152 million by 2050.
Why it matters
This overview describes Alzheimer's disease as a global health crisis affecting over 58 million people as of 2020, with projections reaching 152 million by 2050. It states that the pathogenesis is multifactorial, involving amyloid-β plaque accumulation, tau hyperphosphorylation and other factors.
-
Older age, White race, APOE ε4 carrier, and diabetes were associated with biomarker levels indicative of higher AD risk (lower Aβ42/40; higher p-tau217, p-tau217/Aβ42, NfL, and GFAP).
Why it matters
In midlife adults, blood markers indicating more Alzheimer's pathology and nerve injury were linked to worse performance on tests of processing speed, executive function and other thinking domains. The authors conclude that Alzheimer's-related processes may already affect thinking in midlife, making young and middle adulthood a critical time for prevention efforts.
-
Of the 75 LOAD associated loci, 52 had at least one variant in the top1% of |nSL| in two populations from the 1000 Genomes data.
Why it matters
At least 26 late-onset Alzheimer's disease risk loci show evidence of recent evolutionary selection, with distinct biological processes implicated in different superpopulations. Research and interventions may need to be tailored to superpopulation-specific etiology and comorbidity patterns.
-
AcTau174 levels were elevated in all dementia groups compared to controls, with a stepwise increase from controls to MCI-AD (2.2-fold) to AD dementia (3.5-fold, Figure 1).
Why it matters
This study found that a form of acetylated tau in spinal fluid was elevated in several dementias and was linked to faster cognitive decline. It may help diagnose and predict progression, but it is a biomarker study and does not test any treatment.
-
The DET framework has achieved superior performance on the classification task across all the evaluation metrics compared to the traditional machine learning based methods, as demonstrated in Table 1.
Why it matters
This study describes a new computational framework that classified people with Alzheimer's disease, Lewy body dementia and cognitively normal controls better than traditional machine learning methods. It is a technical modeling study and does not test any treatment or prevention.
-
Of 234 patients, 143 (61.1%) were Aβ-positive.
Why it matters
This study identified cutoff scores on one dementia scale that correspond to cognitive thresholds on another scale, which may help identify patients eligible for anti-amyloid therapies. It is a cross-sectional study about assessment and does not test whether the therapies work.
-
This joint Position Paper, developed by the Italian Expert Panel on Alzheimer convened by the Italian Society of Neurology with participation from multiple scientific societies, outlines strategic guidelines for reorganizing the patient journey in the era of anti-amyloid monoclonal antibodies for Alzheimer's disease.
Why it matters
This position paper recommends reorganizing the diagnostic and treatment pathway for anti-amyloid monoclonal antibodies in Alzheimer disease, including early identification, specialized assessment, and accreditation of treatment centers. It is a set of recommendations, not a study of whether these antibodies work or are safe.
-
42/100
Greater TSPO is associated with lower performance in episodic memory, attention/processing speed, executive function, language, and visuospatial ability in amyloid-positive individuals, but restricted to episodic memory in amyloid-negative individuals.
Why it matters
Greater TSPO, a marker of microglial activation, was linked to lower performance across several cognitive domains in amyloid-positive individuals, but only to episodic memory in amyloid-negative individuals. The authors suggest targeting microglia may provide further benefits, but this cross-sectional finding is not itself a treatment or cure.
-
Tri demonstrates significant multi-target neuroprotective effects in AD preclinical models.
Why it matters
This review of preclinical research found 15 studies, out of 403 screened, testing triptolide, a compound from the plant Tripterygium wilfordii, in Alzheimer's disease models. In these cell and animal models it reduced amyloid-beta build-up, improved memory and synapse health, and dampened inflammation and oxidative stress. These are lab results, so the authors call for further high-quality studies on dosing, delivery and safety before it could be tried in patients.
-
42/100
Physical activity was not associated with plasma Aβ42/Aβ40, p-tau217, or brain Aβ burden 7 years later.
Why it matters
In this Rotterdam Study analysis, physical activity was not associated with plasma Aβ42/Aβ40, p-tau217 or brain Aβ burden 7 years later, and reallocating sedentary time to activity showed no link with these Alzheimer's disease biomarkers. The authors suggest physical activity might affect dementia risk through other pathways or in an earlier life phase, but this study found no link with these biomarkers.
-
From 1992 to 2021, ADOD incidence among individuals aged ≥55 increased by 143.88%.
Why it matters
The global burden of Alzheimer's disease and other dementias among adults aged 55 and above increased substantially from 1992 to 2021, with the steepest rise in the 60-64 age group and higher rates in females. Projections suggest a slight increase in incidence and mortality by 2046, highlighting the need for region-specific interventions.
-
The advent of anti-amyloid therapies (AATs) for Alzheimer disease (AD) has elevated the importance of MRI surveillance for amyloid-related imaging abnormalities (ARIA) such as microhemorrhages and siderosis (ARIA-H) and edema (ARIA-E).
Why it matters
An FDA-cleared AI decision support tool improved sensitivity for detecting subtle ARIA-E and ARIA-H lesions on MRI but reduced specificity. The authors propose a tiered workflow combining protocol harmonization and expert interpretation with AI overlay review, noting both promise and pitfalls for patient safety as disease-modifying therapies gain broader use.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations
- Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study
- Amyloid PET Ligands for Dementia
- Early onset Alzheimer's disease is associated with a distinct neuropsychological profile
- Genetic association of ABCA7 and PSEN1 polymorphisms with Alzheimer’s disease in the northeast Algerian population: Exploring risk factors
- Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease
- Orexin, Sleep, and Cognition in Alzheimer Disease: Non-REM Oscillatory Activity and Neural Resilience
- Cost-Effectiveness of Donanemab for Early Alzheimer Disease in Australia
- Acute procoagulant stress response as a dynamic measure of allostatic load in Alzheimer caregivers
- Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease